Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response -- more

Claros - Runner-Up Medical Devices - Wall Street Journal's 2011 Technology Innovation Awards -- more

OPKO Health Announces Acquisition of Claros Diagnostics -- more

Enanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic -- more

Glori Energy jumps on IPO bandwagon -- more

Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch -- more

Glori Energy: Oil-loving bugs enhance recovery in old and new reservoirs -- more

ExonHit - Brain center to join clinical trial involving Alzheimer's -- more

SuperGen, Inc. Changes Name To Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol And New Website -- more

superDimension Raises $11 Million in Equity Financing -- more

SuperGen Reports 2011 Second Quarter Financial Results -- more

Exonhit and BGI announce successful completion of a promising next-generation sequencing project -- more

Exonhit and BGI announce successful completion of a promising next-generation sequencing project -- more

SuperGen Completes Acquisition of Astex Therapeutics -- more

Exonhit announces successful completion of the second phase of EHT Dx14 clinical validation -- more

Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics -- more

Glori Energy, a Low-Cost Oil Recovery Company, Receives Boost from Energy Technology Ventures—a GE-NRG Energy-ConocoPhillips Venture -- more

Luca Technologies Files Registration Statement for Initial Public Offering -- more

Tragara Pharmaceuticals’ Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis -- more

Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study -- more

Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis -- more

New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation -- more

Astex wins £5.9m GSK milestone windfall -- more

Ensemble Therapeutics Achieves Milstone in Bristol-Myers Squibb Collaboration -- more

Cambrios Provides ClearOhm Film for Smartphones -- more

SuperGen and Astex Therapeutics Enter Definitive Merger Agreement -- more

ExonHit announces publication of EHT 0202 Phase IIa results in Current Alzheimer Research -- more

superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit -- more

Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C -- more

Cambrios: Nissha Started Mass Production of Touch Sensor Films Using Metal Nanowires -- more

ExonHit announces successful completion of the first phase of EHT Dx14 ongoing clinical validation -- more

ExonHit Therapeutics reports 2010 results -- more

ExonHit announces CE marking of AclarusDx™ -- more

IntraPace: Stomach pacemaker could help obese lose weight -- more

VaxInnate Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines -- more

VaxInnate: HHS awards contracts to develop new flu vaccine technology -- more

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia -- more

Rib-X Initiates Antibiotic Drug Trial -- more

Astex Receives Milestone from Wellcome Trust for Pioneering HCV Research -- more

IntraPace Receives CE Mark Certification for the abiliti® System for the Treatment of Obesity -- more

Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases -- more

Technology Review: The Year's Best Tech Products (Claros Diagnostics) -- more

AVEO's Tivozanib in Combination with Paclitaxel Demonstrates Safety in Patients with Metastatic Breast Cancer; Data Presented at San Antonio Breast Cancer Symposium -- more

Asterand to settle final payment for BioSeek acquisition with cash -- more

Dicerna Pharmaceuticals and Kyowa Hakko Kirin Expand Dicer Substrate Technology Partnership into Immunologic and Inflammatory Diseases -- more

Encouraging Data on Astexs' Anti-Cancer Drug AT9283 to be Presented at ASH -- more

OSI Pharmaceuticals, Inc. Exercises Option under Discovery and Translational Research Collaboration with AVEO -- more

AVEO's Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium -- more

AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors -- more

Encouraging Data from Phase I Studies of Astex's Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting -- more

ExonHit presents promising data on genomic biomarkers in Alzheimer's disease clinical trials -- more

Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma -- more

VaxInnate's Novel Recombinant Flu Vaccine Named a Top 10 Biopharma Project to Watch in 2011 -- more

Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/R for Treatment of Hepatitis C -- more

Coherex Medical Expands Portfolio with New Medical Device; New Heart Implant Treats Patients at Risk for Stroke -- more

Milestone Transition in Astex Alzheimer's Disease Collaboration with AstraZeneca -- more

Dicerna Pharmaceuticals Announces Second Close of Series B Financing -- more

National Cancer Institute awards contract to Asterand, valued at up to $24.3 million -- more

Asterand's Subsidiary BioSeek Signs Agreement with Cellzome -- more

Dalia Cohen Ph.D. Joins Asterand as Chief Scientific Officer -- more

Targeson Inc. appoints Origin Biosciences Inc. as Chinese Distributor -- more

ExonHit Therapeutics ' Strong growth of half-year 2010 results -- more

Dicerna Pharmaceuticals Named One of the 'Fierce 15' Leading Biotech Companies of 2010 -- more

Targeson, Inc. appoints Kingyoup Enterprises Co., Ltd. as Taiwan Distributor -- more

Tragara Pharmaceuticals Initiates Phase I Clinical Program for TG02 -- more

superDimension Raises $24.8 Million in Debt and Equity Financing -- more

Energy Grasses Take Center Stage at Ceres Field Day -- more

Santhera Obtains European Patent for Use of Catena'/Sovrima' in the Treatment of Muscular Dystrophies -- more

Trubion Pharmaceuticals Announces Agreement to be Acquired by Emergent BioSolutions -- more

Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma -- more

Dicerna Closes $25 Million Series B Financing -- more

Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry -- more

GE Capital Provides $5 Million Credit Facility To Mitralign, Inc. -- more

VaxInnate: Two Start-Ups Aim To Change Economics Of Vaccine Production -- more

Fairfield County resident, Cornelius T. Ryan, named one of the 'Irish Life Science 50' -- more

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program -- more

Gilead Sciences to Acquire CGI Pharmaceuticals for Up to $120 Million -- more

Santhera's Catena' Improved Vision in Patients with Leber's Hereditary Optic Neuropathy; Regulatory Submissions Planned in First Half of 2011 -- more

AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment -- more

ExonHit signs an exclusive agreement with Genmab for novel splice variant targets in breast cancer -- more

BRAINCELLS INC. Announces Results from Exploratory Phase 2A Trial of BCI-540 in Depression with Anxiety -- more

Asterand Signs Agreement with Amylin Pharmaceuticals -- more

ExonHit discloses the final terms of the acquisition of RedPath Integrated Pathology -- more

EPA Extends Asterand's Role in ToxCast ' Program -- more

AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer -- more

Novozymes and Ceres partner on biofuel crops -- more

Scientists Weigh Use of Bacteria for Cleaner Fossil Fuel Production -- more

BrainCells Issued First U.S. Patent for Drug Combinations that Modulate Neurogenesis -- more

VaxInnate's VAX125 Seasonal Flu Vaccine Shown Safe and Highly Immunogenic in Phase II Study of Elderly Subjects -- more

ExonHit to acquire RedPath Integrated Pathology, Inc. and accelerate growth in molecular diagnostics -- more

Cardiofocus Secures $5M in Financing -- more

Asterand Sponsors Inaugural Human Tissue Conference -- more

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program -- more

Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010 -- more

ExonHit receives "Innovative Company" accreditation from the French state innovation agency OSEO -- more

Claros: Prostate Cancer Results While You Wait -- more

superDimension: iLogic Video Footage -- more

Dicerna Pharmaceuticals and Ipsen Enter into an Exclusive Research Collaboration for the Development of New Therapeutic Agents in Endocrinology and Oncology -- more

Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million Each to Intellikine, Inc. and Tragara Pharmaceuticals, Inc. to Advance Next-Generation Therapies for Multiple Myeloma -- more

ExonHit presents new data on its Alzheimer's lead candidate at the International Geneva/Springfield Symposium -- more

Rib-X Appoints Mark Leuchtenberger As President And CEO -- more

Molecular Biometrics Receives Frost & Sullivan Technology Innovation Award -- more

Dr. Thomas Hofstaetter Named President and CEO of VaxInnate; Dr. Alan Shaw Assumes New Role as Chief Scientific Officer and Chairman of the Board -- more

AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering -- more

ExonHit reports out-licensing of EHT/AGN 0001 -- more

Molecular Biometrics Announces Launch of Viametrics-E' -- more

Abbott and Enanta Announce Advancement of Hepatitis C Collaboration-- Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals -- more

Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program -- more

ExonHit announces the inclusion of proprietary lead compounds into Allergan collaboration -- more

ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer's disease -- more

Astex Executive Receives the AstraZeneca Business Development Professional of the Year 2009 Award -- more

Tragara Raises $5M -- more

Molecular Biometrics Closes $12.5 Million Series B Equity Funding -- more

Ensemble Discovery Initiates Collaboration with Pfizer to Develop Novel Drugs Against Protein-Protein Interaction Targets -- more

Circulite' closes on Series C Financing -- more

Dicerna Signs Research Collaboration and License Agreement for Drug Delivery Systems and Dicer Substrate siRNA (DsiRNA) Pharmaceuticals with Kyowa Hakko Kirin -- more

Astex Wins Company Newsflow of the Year Award -- more

Former Wyeth Executive Joins VaxInnate as Chief Operating Officer -- more

HydroCision Introduces a New Low Profile Device For Minimally Invasive Endoscopic Discectomy Market -- more

Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board -- more

Asterand Announces Extension of Agreement with Bristol-Myers Squibb -- more

Astex Announces Strategic Drug Discovery Alliance with GlaxoSmithKline -- more

Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC Annual Meeting 2009 -- more

Santhera Receives Grant from Association Fran'aise contre les Myopathies for its Omigapil Program in Congenital Muscular Dystrophy -- more

Astex Announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387 -- more

Lung Cancer Diagnosis Breakthrough from superDimension Receives Category I' CPT Reimbursement Codes -- more

superDimension Launches Second Generation iLogic'Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer -- more

ExonHit will participate in the MAPT study for the prevention of cognitive decline in old people -- more

superDimension, Inc.: Company Expects Broadened Physician Adoption for Minimally Invasive Technology That Offers Potential to Change Standard of Care -- more

ExonHit presents new clinical advances on its Alzheimer's diagnostic and therapeutic programs -- more

BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman -- more

Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry -- more

Coherex Medical Signs Exclusive Distribution Agreement with Abbott -- more

Mount Sinai First In Nation to Ablate Atrial Fibrillation Using New Visually-Guided Balloon Catheter -- more

AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors -- more

NeuroInvestment : BrainCells and Neurogenesis: Proof of Principle and More -- more

Luca Technologies Named a Global Cleantech 100 Clean Technology Company by the Guardian and Cleantech Grouptm -- more

NeuroInvestment: Company Spotlight - BrainCells Inc. -- more

Coherex Medical Closes $16.5 Million Series B Preferred Stock Financing -- more

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis -- more

Pathway PV Atherectomy System: The Best Designs of 2009 - Business Week -- more

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression -- more

OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration -- more

Asterand Signs Global Agreement with Lundbeck Giving Access to its Human Tissue Samples and Drug Discovery Services -- more

Dicerna Pharmaceuticals Announces Appointment of Industry Veteran David Madden as Chairman of the Board -- more

CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter -- more

Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena' in MELAS -- more

Santhera and NIH Collaborate To Evaluate Catena' in Primary Progressive Multiple Sclerosis -- more

Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration -- more

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) -- more

AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer -- more

ExonHit and Institut Gustave Roussy Announce the Signing of a License Agreement for Novel Breast Cancer Diagnostic Assay -- more

Pathway Medical Technologies Closes $42.5M Series D Financing; Announces New Investment From WRF -- more

Ceres Yield Results: Energy Crop Benefits are Greatly Underestimated -- more

Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company; Completes $12M Equity Financing -- more

ZettaCore Raises $21M; Panasonic Makes Strategic Investment -- more

VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round -- more

Forbes Magazine - VaxInnate: The Flu Vaccine Accelerator -- more

Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board -- more

Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory -- more

VaxInnate's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study -- more

Asterand Announces Collaborative Agreement to Characterise Antibodies -- more

Astex Presents Key Data Differentiating its Phase I HSP90 inhibitor, AT13387, at the AACR Annual Meeting 2009 -- more

Astex Reports Positive Clinical Biomarker Data from its Phase I study on CDK Inhibitor AT7519 at the AACR Annual Meeting 2009 -- more

High-Yielding Switchgrass the Focus of Ceres and University of Georgia Researchers -- more

Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation -- more

Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009 -- more

Astex Achieves Milestones in Drug Discovery Collaboration -- more

BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer -- more

CircuLite Demonstrates Long-Term Improvements and Hemodynamic Benefits with Synergy' Partial Circulatory Support in Chronic Heart Failure Patients -- more

Astex Awarded '2 Million from Wellcome Trust for Pioneering HCV Research -- more

Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes -- more

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies -- more

BrainCells Inc. Selected to Present at InsideVenture's Debut Investor Conference - March 25-26, Santa Barbara, California -- more

Wide-Ranging Restructuring Bears Fruit for Asterand -- more

Claros Diagnostics Inc: Innovation in Tough Times -- more

CircuLite' Completes Initial Close on $33 Million Series C Financing Plan and Appoints Chief Medical Officer -- more

AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer -- more

Seahorse Bioscience, Inc. acquires BioProcessors Corp. -- more

Antisoma: Well-funded, late-stage M&A target -- more

Xencor and Pfizer enter into Antibody Technology Licensing Agreement -- more

Astex Receives Award from the Multiple Myeloma Research Foundation to Support Clinical Development of AT7519 -- more

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, Its Phase II Drug for Alzheimer's Disease -- more

Xencor and CSL Limited Establish Antibody Optimization Collaboration -- more

Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers -- more

Concentric Medical Expands Product Offering in Neuro Access -- more

Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing -- more

Concentric Medical Reaches Important Stroke Milestone -- more

S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 -- more

AngioDynamics Acquires FlowMedica Benephit(R) Renal Therapy Product Line -- more

Concentric Medical Closes on $15 Million Financing -- more

Ceres: First Seed Sales of Dedicated Energy Crops Begin -- more

Santhera Enrolls Last Patient in European Phase III Trial Evaluating SNT-MC17/Idebenone in Friedreich's Ataxia -- more

Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin -- more

BrainCells Inc. Appoints David E. Thompson to its Board of Directors -- more

Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million -- more

Santhera Presents Preclinical Data on Oral MC4 Receptor Antagonists for Treatment of Cancer Cachexia at AICR Research Conference -- more

Santhera Raises CHF 15.9 Million in Private Placement with Strategic Investor Ares Life Sciences -- more

Critical Therapeutics, Inc. Announces Stockholder Approvals Related to Merger with Cornerstone BioPharma Holdings, Inc. and 10-to-1 Reverse Stock Split -- more

Santhera Enrolls Last Patient in Pivotal US Phase III with SNT-MC17/Idebenone in Friedreich's Ataxia -- more

Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis -- more

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC / IDSA Joint Meeting -- more

Concentric Medical Launches Distal Access Catheter -- more

BrainCells Inc: Salk Scientist Fred H. Gage To Receive The Keio Medical Science Prize -- more

Astex presents updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference -- more

Santhera Launches CATENA' in Canada -- more

Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment -- more

Publication in European Heart Journal Highlights Potential of Santhera's SNT-MC17/Idebenone in Duchenne Muscular Dystrophy -- more

AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and Lymphomas -- more

Concentric Medical to Sponsor Randomized Trial -- more

Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program -- more

Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic with Activity Against Hospital- and Community-Acquired MRSA -- more

Ceres Trials Energy Crops at Georgia Biofuel Facility -- more

Pathway Medical Technologies Receives FDA Clearance for JetstreamTM Pathway PVTM Atherectomy System -- more

Asterand to Enter Into Exclusive License Agreement with Allergan for Pre-Clinical Compounds Focused on Diseases of the Eye -- more

AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and Other Gastrointestinal Cancers -- more

Santhera's 2008 Interim Results Reflect Advances in Clinical Development and Preparation for First Product Launch -- more

VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study -- more

Santhera's Omigapil Receives Orphan Drug Designation from FDA and EMEA -- more

Cardiome and Astellas Announce Receipt of FDA Approvable Letter for KYNAPID -- more

Santhera Provides Update on Clinical/Regulatory Processes with SNT-MC17/Idebenone for the Treatment of Friedreich's Ataxia -- more

Memory Pharmaceuticals Presents Positive Preclinical Data for MEM 68626 at ICAD 2008 -- more

Santhera Receives First Product Approval: Health Canada Approves Catena' for Treatment of Friedreich's Ataxia -- more

Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 in Complicated Skin and Skin Structure Infections -- more

Cardiome Announces Positive Phase 2b Results for Oral Vernakalant -- more

Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting -- more

Critical Therapeutics Announces Stock Listing Transfer From NASDAQ Global Market to NASDAQ Capital Market -- more

llumina Announces Participation in the 1000 Genomes Project -- more

Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. -- more

Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions -- more

Loic Maurel Joins ExonHit Therapeutics to Become CEO -- more

Trubion Announces Presentation of Positive TRU-016 Data at ASCO -- more

Critical Therapeutics Completes Phase II Clinical Trial for Zileuton Injection -- more

AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell -- more

Elixir Pharmaceuticals Researchers Publish New Data Validating Ghrelin as a Key Metabolic Regulator -- more

Dynogen Presents Results of Its Positive Phase 2a IBS-c Study with DDP733 -- more

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 -- more

Critical Therapeutics Signs Definitive Agreement to Merge with Cornerstone BioPharma -- more

Dynogen to Present Positive Clinical Data For DDP225 And DDP733 At Digestive -- more

Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science -- more

Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis -- more

Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting --


more

BrainCells Inc. Expands Series B Financing to $50 Million -- more

Xanthus' Symadex Reverses Disease in Preclinical Mouse Models of Multiple Sclerosis -- more

Pathway Medical Technologies, Inc. Secures $24.5 Million Financing -- more

Xanthus Presents Data Supporting Distinctive Mechanism of Action for Xanafide' -- more

Santhera Presents Clinical Efficacy Data of SNT-MC17 in DMD at the American Academy of Neurology Annual Meeting -- more

Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA -- more

Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis -- more

ExonHit Appoints a New Management Board -- more

Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update -- more

Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug -- more

BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing -- more

February 29, 2008: Santhera Reports Financial Results and Significant Operational Progress for 2007 -- more

Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer -- more

Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance -- more

Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement -- more

Mitralign Successfully Completes First Human Case -- more

AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma -- more

Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes 'CTA Acceptance in the Netherlands Triggers Milestone Payment to Eisai -- more

Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA -- more

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors -- more

ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule -- more

Critical Therapeutics Receives $5.0 Million Milestone Payment from DEY for Commercial Launch of ZYFLO CR -- more

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project -- more

Coherex Medical Hires Top Medical Industry Veteran to Fill Global Market Development Seat -- more

Mitralign Announces Closing of Series C Financing -- more

Health Canada Accepts Santhera's Submission for Marketing Authorization of SNT-MC17 in Friedreich's Ataxia -- more

Dicerna, Startup Based on RNAi Biology, Licenses IP from City of Hope and Closes $13 Million Series A Financing -- more

Santhera Showcases Potential and Progress of its Clinical Development Pipeline -- more

Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease --

more

ExonHit Completes a Prototype to Detect Alzheimer's Disease from Blood -- more

Results from Phase 1 Study of AVEO's Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease -- more

Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease -- more

AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer -- more

Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies -- more

Santhera Reports Encouraging, First Data from Phase IIa Clinical Trial with SNT-MC17 in Duchenne Muscular Dystrophy -- more

Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer -- more

Santhera's CSO Thomas Meier Receives BioValley Award for Scientific and Entrepreneurial Merits -- more

Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study -- more

Critical Therapeutics Announces Enrollment in Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD -- more

Critical Therapeutics Announces the Issuance of Four New Patents for Its Alpha-7 and HMGB1 Preclincial Programs -- more

Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia -- more

Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol Fumarate) Inhalation Solution -- more

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia -- more

Coherex Medical, Inc., a privately held medical device company,today announced it has successfully completed the first human cases of its Coherex FlatStent(TM) PFO Closure System -- more

AVEO Pharmaceuticals to Utilize Peptech's Breakthrough Technology to 'Humanise' Internal Drug Candidates -- more

OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration -- more

Critical Therapeutics Initiates Phase I Clinical Trial of the R(+) Isomer of Zileuton -- more

Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design -- more

Ceres Raises $75 Million in Late-Stage Financing -- more

BrainCells Inc., Taisho Pharmaceutical Co., Ltd. Sign Licensing Agreement for Novel CNS Program -- more

Critical Therapeutics and Dey Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets -- more

Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development -- more

Elixir Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering -- more

Santhera to Seek Canadian Market Approval for SNT-MC17 in Friedreich's Ataxia -- more

Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis -- more

Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells -- more

Critical Therapeutics Announces Publication of Results from Two Asthma Studies -- more

Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis -- more

Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia -- more

Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 -- more

FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry -- more

Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials -- more

Concentric Medical, Inc. Files Registration Statement for Proposed Initial Public Offering -- more

Santhera's 2007 Interim Results Reflect Increased Investment in Advanced Development Pipeline -- more

European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera -- more

BioProcessors Raises $10 Million -- more

Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy -- more

Elixir Pharmaceuticals to Present Data from Programs to Treat and Prevent Metabolic Diseases -- more

Intechra Adds National Logistics Network, Two Acquisitions -- more

Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial -- more

Critical Therapeutics Initiates Phase IV Study Evaluating ZYFLO CR(TM) in Asthma Patients on Inhaled Corticosteroids Whose Symptoms Are Poorly Controlled -- more

Santhera Licenses Omigapil for Treatment of Rare Neuromuscular Diseases -- more

Critical Therapeutics' Zileuton Provides Additional Asthma Control When Combined with Inhaled Corticosteroids -- more

ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia -- more

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting -- more

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes -- more

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -- more

AVEO Pharmaceuticals' CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur of the Year' Award -- more

Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia -- more

Critical Therapeutics Announces the Publication of Data for ZYFLO CR(TM) (Zileuton) Extended-Release Tablets in the Journal of Asthma -- more

ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis -- more

Agilent Technologies Adds Strength to Its Life Science Business with Acquisition of Stratagene -- more

Dynogen Reports Positive Results in Phase 1B GERD Study -- more

Cardiome and Astellas Announce Positive Results from ACT 2 Trial -- more

Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer -- more

Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML -- more

FDA Approves Critical Therapeutics' Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for Asthma -- more

Intechra Secures Additional $30 Million in Equity Capital -- more

Solstice Neurosciences, Inc. Announces Commercialization Agreement -- more

Critical Therapeutics' Sales Force Gains Access to a Second Product as FDA Approves Co-Promotion Partner's New Treatment for COPD -- more

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex -- more

AVEO Pharmaceuticals Closes $53 Million in Series D Funding -- more

Critical Therapeutics' Co-Promotion Partner, DEY, L.P., Launches U.S. Sales and Marketing of ZYFLO(R) for Asthma -- more

CircuLite Closes an Additional $5M in Series B Private Placement Funding -- more

Xanthus Acquires from Johns Hopkins University Exclusive License to Patent Estate Covering FLT3 Pathway as a Target for Treating Autoimmune Diseases -- more

Stratagene Signs Definitive Agreement to Be Acquired by Agilent Technologies -- more

Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease Trial -- more

AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody -- more

ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering -- more

Radius Raises $57.5 Million in Second Private Financing Round -- more

Nfocus Neuromedical Inc. Raises over $20 Million in Series B Financing -- more

Santhera Announces Appointment of Cesare Mondadori as Head of Research -- more

BrainCells and Lundbeck Form CNS Drug Research Collaboration -- more

Xanthus Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors -- more

Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis -- more

ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial -- more

ExonHit Identifies a Panel of Genes to Diagnose, From Blood, Alzheimer's Disease -- more

Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing -- more

Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products -- more

Memory Pharmaceuticals Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease -- more

Avalon Pharmaceuticals and Merck & Co., Inc. Establish a Drug Discovery, Development and Commercialization Collaboration -- more

Lilly Announces Acquisition of Hypnion -- more

FlowMedica: Targeted Renal Therapy for Patients at Risk for Contrast-Induced Nephropathy -- more

Asterand Offers Researchers Internet Access to RNA to Speed Drug Discovery -- more

Santhera Reports Successful 2006 -- more

Santhera Board Proposes the Election of Klaus Schollmeier to the Company's Board -- more

Cyberkinetics Files to Market Andara(TM) OFS(TM) Therapy for Acute Spinal Cord Injury under Humanitarian Device Exemption -- more

Critical Therapeutics Announces Beckman Coulter Exercises Option to Continue HMGB1 Diagnostic Development -- more

Elixir Pharmaceuticals and Siena Biotech S.p.A. Enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease -- more

Dynogen Reports Positive Results in Phase 2 IBS-c Study -- more

Santhera Intends Early Filing in Europe for SNT-MC17/idebenone in Friedreich's Ataxia -- more

Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US -- more

Critical Therapeutics Licenses Rights for Vagus Nerve Stimulation Device to Innovative Metabolics -- more

Claros Diagnostics Secures $7.8 Million Series A Financing to Develop Handheld Point-of-care Diagnostics Platform -- more

Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes -- more

Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis -- more

Solexa Genome Analysis System Achieves 1G Performance Milestone -- more

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin -- more

Cohesive Technologies Inc.: Thermo Fisher Scientific Acquires Provider of Sample Extraction and Liquid Chromatography -- more

Critical Therapeutics Announces NIH-Sponsored Study to Investigate the Efficacy Of ZYFLO(R) In Patients with Acute Exacerbations Of COPD -- more

Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors -- more

Xanthus Presents Preclinical Data Demonstrating Potent Symadex Activity in Leukemia Cells -- more

Memory Pharmaceuticals Announces Release of Clinical Hold on MEM 3454 -- more

Xanthus Completes Enrollment of Phase 2 Trial of Xanafide for the Treatment of Secondary AML -- more

Astex Therapeutics Appoints John Aston Chief Financial Officer -- more

Xanthus Secures $25 Million to Advance Development of Its Pipeline -- more

Santhera and Biozentrum Basel participate in the pan-European TREAT-NMD initiative to advance the treatment of rare neuro-muscular diseases -- more

ImpactRx, Inc. Names Altus President and Chief Executive Officer -- more

Memory Pharmaceuticals Completes Enrollment for MEM 1003 Bipolar Trial -- more

Memory Pharmaceuticals Earns Milestone Payment for Phase 2a Trial of MEM 1003 in Bipolar Disorder -- more

The Leukemia & Lymphoma Society and Ensemble Discovery Corp. Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers -- more

NIH and Santhera Announce Positive Results of Study with SNT-MC17/idebenone in Friedreich's Ataxia -- more

Solstice Neurosciences Raises $85 Million in Private Financing -- more

Mitralign Shines at TCT 2006; Performs Live Case & Reveals Clinical Strategy -- more

Pathway Medical Closes $25 Million in Funding -- more

Critical Therapeutics Announces Closing of $20.0 Million Registered Direct Offering -- more

Memory Pharmaceuticals to Receive $2 Million Milestone from Roche Related to MEM 3454 -- more

Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. -- more

Critical Therapeutics Outlines New Business Strategy Focusing on Controlled-Release and Intravenous Formulations of Zileuton -- more

Critical Therapeutics to Sell 7.5 Million Shares of Registered Common Stock and Warrants to Purchase 3.7 Million Shares of Common Stock -- more

VaxInnate Secures $40 Million Series C Financing -- more

Asterand Isolates New Approach to Arthritis Research -- more

Alantos Pharmaceuticals and Servier Form Collaboration -- more

AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors -- more

VaxInnate Reports Promising Results for Novel Influenza Vaccine Candidates -- more

BrainCells and Organon to Collaborate in Discovery and Development of CNS Drugs -- more

ExonHit to Identify a Blood Diagnostic for Atherosclerosis -- more

Cyberkinetics Enters into Definitive Agreements for $10.0 Million Private Placement -- more

Solexa Announces Sequencing of a Human X-Chromosome -- more

Critical Therapeutics Announces Acceptance of Controlled-Release Zileuton New Drug Application for Review by FDA -- more

Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG -- more

Biopharmaceutical Firm Trubion Plans 4 Million IPO Shares -- more

Technology behind Sirna Therapeutics subject of the 2006 Nobel Prize for Physiology and Medicine -- more

Memory Pharmaceuticals Achieves Milestone in PDE10 Collaboration With Amgen -- more

Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model -- more

AVEO and XOMA Enter Into Supply Agreement for AVEO's Novel Anti-HGF Antibody -- more

ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia -- more

Santhera Appoints MJ Roach as Vice President Marketing and Sales -- more

Kurt H. Kruger Joins Cyberkinetics as Chief Financial Officer -- more

ExonHit Therapeutics Extends Strategic Alliance with Allergan -- more

Santhera Appoints New Board Directors -- more

Xanthus Presents In Vitro Data Demonstrating that Symadex Is a Potent and Selective Inhibitor of FLT3 -- more

Dynogen Initiates Phase 1b Trial of DDP733 in Gastroesophageal Reflux Disease (GERD) ' New Approach for Treating Nighttime Heartburn -- more

Radius & Karo Bio Announce Licensing Agreement for Novel SARM Compounds -- more

FDA Grants Humanitarian Use Device Designation to Cyberkinetics' Andara(TM) OFS Device for Acute Spinal Cord Injuries; Designation Marks Critical Regulatory Step Toward Commercialization -- more

Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin -- more

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 1003 in Bipolar Disorder -- more

Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson's Disease -- more

Exelixis Files IND Application for XL228 -- more

Solexa Appoints Blaine Bowman and Roy Whitfield to Board of Directors -- more

Critical Therapeutics Announces Results of Phase I/II Trial of Intravenous Formulation of Zileuton -- more

Sirna Therapeutics Reports Final Results from Phase 1 Study on Its RNAi-Based Therapeutic for Age-Related Macular Degeneration -- more

BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma -- more

Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists -- more

Solexa Appoints Joseph Whitters to Board of Directors -- more

Critical Therapeutics Submits New Drug Application for Controlled-Release Formulation of Zileuton To FDA -- more

Memory Pharmaceuticals Achieves Milestone Under Nicotinic Alpha-7 Collaboration With Roche -- more

Cyberkinetics' Neural Sensing Technology Highlighted in Second Study Published in Nature -- more

MicroMed Announces Hiring of Alan Totah as Senior Vice President of Regulatory Affairs and Quality Systems -- more

Solexa Announces Initial System Shipments; Early Access Program Underway with Leading Genome Institutes -- more

Ceres Announces Genomics Milestone in Energy Crop Enhancement Program -- more

PowderMed to Conduct Clinical Trial of its Novel DNA-Based H5N1 (Avian) Influenza Vaccine in London -- more

Asterand signs partnership to supply drug discovery services to Japan -- more

Solexa Joins Russell 3000 Index -- more

Asterand Announces Collaboration with Rubicon Genomics to Develop New Cancer Diagnostic Tests -- more

Cyberkinetics Reports Preliminary BrainGate Data from Non-Speaking, Paralyzed Participant at ASIA Meeting in Boston -- more

Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs -- more

European Patent Office Significantly Limits Scope of Kreutzer-Limmer RNAi Patent Claim -- more

Rib-X Pharmaceuticals Raises $50 Million in Series C Financing -- more

MicroMed Announces Closing of $15.425 Million Financing -- more

Ceres and Noble Foundation Establish Collaboration for New Energy Crops -- more

Cyberkinetics Reports First Data from Non-Speaking, Paralyzed Participant in Ongoing Study of BrainGate Neural Interface System - Expanded Evidence of Brain Computer Interface Utility Presented at ASSFN Meeting in Boston -- more

Xanthus Presents Symadex Phase 1 Results at American Society of Clinical Oncology Meeting -- more

Xanthus Meets Milestone in Phase 2 Clinical Study of Xanafide for Treatment of Secondary AML -- more

Trubion Files for Initial Public Offering -- more

Rib-X Pharmaceuticals and Wakunaga Pharmaceutical Company Announce License Agreement for Quinolone Antibiotic -- more

Cyberkinetics and Minnetronix Finalize Design and Manufacturing Agreement for the Andara OFS Device to Treat Acute Spinal Cord Injuries -- more

UMass Medical School Partners with PowderMed to Test Potential Avian Flu Vaccine -- more

Study in the Journal "Vaccine" Reports Positive Results of DNA-Based Flu Vaccine in Humans -- more

Sirna Therapeutics Announces Pricing of Common Stock Offering -- more

Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development -- more

Solexa Added to NASDAQ Biotech Index -- more

Sirna Therapeutics Licenses Worldwide Exclusive Rights to microRNA Technology from University of Massachusetts Medical School -- more

Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline -- more

Critical Therapeutics on Target to Submit NDA for Zileuton Controlled-Release Tablets in Third Quarter 2006 -- more

CardioFocus Completes Series C Financing; H.I.G. Ventures and KBL Healthcare Ventures Lead $21.5 Million Round for Developer of First Endoscopically-Guided Catheter Ablation System to Treat Atrial Fibrillation -- more

Asterand Announces New Test to Reduce Risks in Human Drug Trials -- more

Targacept Announces Pricing of Its Initial Public Offering -- more

Radius Appoints Louis O'Dea Senior Vice President and Chief Medical Officer -- more

HydroCision receives 2006 'Medical Design Excellence Award' (MDEA) for its SpineJet' MicroResector -- more

GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease -- more

PowderMed's Therapeutic DNA Vaccine for Chronic Hepatitis B Enters Phase 1 Clinical Trials in Patients -- more

ExonHit and BioM'rieux reach an important research milestone in the molecular detection of breast cancer from blood samples -- more

Elixir Pharmaceuticals Acquires Late-Stage Product for the Treatment of Type II Diabetes -- more

ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease -- more

Dynogen Initiates Phase II Trial of DDP225 for Treatment of Chronic Functional Vomiting -- more

Sirna Therapeutics Announces Its Scientific Advisory Board -- more

X-Cell Begins Trial of its Ethos DES Product Using Estradiol -- more

X-Cell Medical Initiates Enrollment for ETHOS II Clinical Trial of Estradiol Eluting Stent -- more

R. Scott Greer Named Chairman of the Board of Sirna Therapeutics and Lutz Lingnau Appointed as New Board Member -- more

Inverness Medical Innovations Acquires CLONDIAG Chip Technologies -- more

Memory Pharmaceuticals Expands Roche Nicotinic Alpha-7 Alliance -- more

X-Cell Medical: Putting Safety First -- more

Solexa Transfers Listing to The Nasdaq National Market -- more

ExonHit Therapeutics Will Begin Continuous Trading on Alternext -- more

Critical Therapeutics Completes Dosing of First Patient in Clinical Trial of Intravenous Zileuton -- more

ExonHit SpliceArray Service Welcomes Its 50th Commercial Contract -- more

Dr. Derek M. Winstanly Joins Xanthus Life Sciences' Board of Directors -- more

Astex grants Cytochrome P450 license to Pfizer -- more

Solexa Completes Second Closing of $65 Million Private Equity Financing -- more

Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia -- more

Targacept Files for Initial Public Offering -- more

Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients with Metastatic Colorectal Cancer -- more

Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in Cancer Patients -- more

AVEO Pharmaceuticals Acquires Rights to Novel Anti-Cancer Compound from Mitsubishi Pharma Corporation -- more

Wyeth Announces Strategic Collaboration with Trubion Pharmaceuticals -- more

Santhera Announces Management Buy-Out of the Graffinity Drug Discovery Technology Business -- more

Xanthus Initiates Phase 2 Clinical Trial with Symadex in Women With Metastatic Breast Cancer -- more

Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement -- more

Richard W. Dugan Joins Xanthus Life Sciences' Board of Directors -- more

Inverness Medical Innovations Receives FDA Clearance for Sale of its Albumin Cobalt Binding (ACB(R)) Test for Detection of Ischemia Modified Albumin (IMA(R)) on Roche Chemistry Analyzers -- more

Exelixis and Wyeth Sign License Agreement Related to Novel Treatments for Metabolic and Liver Diseases -- more

Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program -- more

Critical Therapeutics Initiates Pharmacokinetic Studies of Zileuton Controlled-Release Tablets; Data to support New Drug Application for twice-a-day formulation of zileuton -- more

Santhera Raises CHF 25 million ('16 million) Via a Further Closing of its 2005 B Financing Round -- more

Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd. -- more

Memory Pharmaceuticals Announces Agreement with the Stanley Medical Research Institute for the Development of MEM 1003 for Bipolar Disorder -- more

Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer's Patients -- more

Exelixis Initiates Phase II Clinical Program for XL999 -- more

Critical Therapeutics to Initiate Clinical Study of Intravenous Formulation of Zileuton; Phase I/II Asthma Study Scheduled to Begin in the First Quarter of 2006 -- more

Santhera Starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedrich's Ataxia -- more

Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 -- more

Solexa Introduces the Solexa Genome Analysis System -- more

Critical Therapeutics Achieves Collaboration Milestone in HMGB1 Program; Demonstrates Efficacy of HMGB1 Antibodies in Preclinical Models of Inflammation -- more

Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Develop Novel Cardiovascular Disease Treatments -- more

Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs -- more

NBC's Today Show Features Cyberkinetics' BrainGate System: In Clinical Trials to 'Turn Thought into Action'; Clinical Trial Participant with Quadriplegia Uses His Own Thoughts to Control a Computer and a Prosthetic Hand -- more

New Paper Highlights ExonHit's Novel Approach for the Treatment of Alzheimer's Disease -- more

X-Cell Medical Completes Enrollment for Clinical Trial of ETHOS I Estradiol Eluting Stent -- more

Solexa Announces Agreement for $65 Million Private Placement -- more

Sirna Therapeutics to Join the NASDAQ Biotechnology Index -- more

Xanthus Life Sciences Appoints J. Kris Piper as Vice President of Regulatory Affairs and Quality Assurance -- more

BioProcessors: Having Identified Rapid, Early Process Development as Critical to the Success of Novo Nordisk's Biologics Programs, Company Chooses SimCell' MicroBioreactor System For High-Throughput Mammalian Cell Culture Process Development -- more

Elixir: Want to Live Forever? -- more

FlowMedica Inc., Completes $15 Million Series D Financing -- more

Critical Therapeutics' Study Suggests Steroid-Sparing Effect of ZYFLO(R) in Patients with Severe Asthma -- more

Memory Pharmaceuticals Commences Phase 2a Trial of MEM 1003 in Alzheimer's Disease -- more

Santhera and the NIH Collaborate to Evaluate SNT-MC17 in Friedreich's Ataxia -- more

Critical Therapeutics' ZYFLO(R) Reduces Need for Rescue Medication and Significantly Improves Lung Function in Severe Asthma Patients -- more

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Prediction -- more

Cardiome Acquires Artesian Therapeutics -- more

Xanthus Initiates a Phase 2 Study Of Xanafide in Combination with ara-C for Treatment Of Secondary AML -- more

Santhera Targets New Indication with its Lead Compound -- more

BrainCells, Inc. Appoints James A. Schoeneck Chief Executive Officer -- more

Memory Pharmaceuticals Announces Collaboration to Develop PDE10 Inhibitors for Central Nervous System Disorders with Amgen -- more

Dynogen Initates Phase II Trial of DDP225 for Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome -- more

Cellzome and Santhera's business unit, Graffinity, awarded Euro 2.2 million grant from German Government -- more

Critical Therapeutics Announces Commercial Launch of ZYFLO(R); Studies Showed ZYFLO Reduced the Need for Rescue Medications and Improved Asthma Symptoms -- more

John P. Donoghue Honored for Cyberkinetics' Groundbreaking BrainGate(TM) Brain-Computer Interface at the 'Popular Mechanics 2005 Breakthrough Awards -- more

Avalon Pharmaceuticals Announces the Activation of IND for AVN944 for the Treatment of Cancer -- more

Avalon Pharmaceuticals Announces Pricing of Initial Public Offering -- more

Xanthus Life Sciences Awarded Grant from NCI to Develop Technology for Personalized Dosing of Anticancer Drugs -- more

Sirna Therapeutics and Allergan Enter Into Strategic Ophthalmology Alliance -- more

Critical Therapeutics Announces FDA Approval of ZYFLO(R) for the Prevention and Chronic Treatment of Asthma; Oral Drug Blocks the Production of Mediators That Can Trigger Asthma Symptoms -- more

Dynogen initiates Phase II trial of DDP733 for treatment of patients with constipation-predominant irritable bowel syndrome -- more

Cyberkinetics Announces $11.4 Million Private Financing -- more

Memory Pharmaceuticals Completes Safety and Tolerability Study of MEM 1003; Preparing to Commence Dosing Patients in Phase 2a Trial -- more

Xanthus Life Sciences Appoints John A. McCarthy, Jr. as Senior Vice President and Chief Financial Officer -- more

Memory Pharmaceuticals Announces $31 Million Financing -- more

Merger of Pharmagene Plc and Asterand, Inc. to Form a Leading Company in Human Tissue Supply and Human Tissue Based Research Services -- more

Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program -- more

ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors -- more

Avalon Pharmaceuticals, Inc. Announces Filing of IND for AVN944 for the Treatment of Cancer -- more

Solexa and Collaborating Scientists Illuminate the Small RNA Component of the Transcriptome; Research Published in ''Science'' Demonstrates the Value of High-Throughput Sequencing in Small RNA Analysis -- more

Astex announces new drug discovery collaboration with Boehringer Ingelheim -- more

Cardiome Announces LOI to Acquire Artesian Therapeutics -- more

Dennis H. Langer Appointed to Sirna Therapeutics Board of Directors -- more

ALS Patients Offered Access to Cyberkinetics' BrainGate(TM) System in New Pilot Study at Massachusetts General Hospital -- more

World Renowned Geneticist David Bentley, D.Phil., Joins Solexa as Chief Scientist -- more

X-Cell Medical Commences Randomized Clinical Trial of Estradiol Eluting Stent -- more

Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases -- more

Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease -- more

PowderMed Manufactures a Vaccine Against HSN1 (Avian Influenza) for Clinical Development -- more

AstraZeneca and Astex announce new anti-cancer drug discovery alliance -- more

BioSource Signs Definitive Merger Agreement and Reports Record Second Quarter Sales -- more

Exelixis Initiates Phase I Clinical Trial for Anticancer Compound XL820 -- more

First Demonstration of Systemic siRNA Efficacy at Therapeutically Relevant Doses is Published by Sirna Therapeutics -- more

BrainCells Inc. Announces $17.7 Million Series A Financing -- more

BioProcessors' SimCell' Platform Demonstrates Potential to Increase Amgen's Cell Culture Experiment Capacity -- more

Solexa Completes $24 Million Private Equity Financing -- more

Sirna Therapeutics Completes Initial Closing of a $28 Million Financing -- more

Elixir Pharmaceuticals: Nature Publication Reports Key Links Between Mechanisms of Aging and Metabolic Disorders -- more

James B. Tananbaum, M.D. Joins Critical Therapeutics' Board of Directors -- more

Cambrios Names Xina Quan as First Vice President of Research & Development -- more

US Tissue Bank, Asterand, Expands Service to Europe -- more

Astex Announces IND Approval for Novel Cancer Drug AT7519 -- more

ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease -- more

Critical Therapeutics Announces Closing of $54.5 Million Private Placement -- more

MedImmune And Avalon Pharmaceuticals Announce Collaboration to Discover Small Molecule Therapeutic Drugs for Inflammatory Diseases -- more

Exelixis Files IND Application for Anticancer Compound XL184 -- more

Sirna Therapeutics Announces Collaboration with Massachusetts General Hospital to Evaluate Potential of siRNAs in Hearing Restoration -- more

Exelixis Announces Transaction to Fund Clinical Development for XL647, XL999 and XL784 -- more

Exelixis and Helsinn Sign Agreement for XL119 (becatecarin) -- more

Detroit's Asterand voted best place to work for scientists -- more

Sirna Therapeutics Publishes Hepatitis B Virus Data in June 2005 Issue of Hepatology -- more

Critical Therapeutics Announces $54.5 Million Private Placement -- more

Two Studies Support Efficacy of Critical Therapeutics' ZYFLO in Moderate to Severe Asthma Patients; Data Presented at the American Thoracic Society's 2005 International Conference -- more

Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months -- more

Detroit Company, Asterand, Named High Technology Company of the Year -- more

Chiron and Enanta Announce Agreement for Development and Commercialization of HCV Therapeutics -- more

Xanthus Presents at ASCO: Phase 1 Data Shows Significant Activity of Amonafide in Combination With ara-C for Treatment of Poor Risk AML -- more

Exelixis Achieves $35 Million in Milestones From GSK -- more

Santhera Presents at the International Congress of Myology -- more

Xanthus Names Robert L. Capizzi, M.D., F.A.C.P. Chief Medical Officer -- more

Avalon Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering -- more

Sirna Therapeutics Announces Results From Interim Analysis of Phase 1 Single Dose Trial With Sirna-027 in Patients With Age-Related Macular Degeneration -- more

Roche Makes Initial Payment of $2 Million to Retain Option to License Memory Pharmaceuticals' MEM 3454 -- more

Santhera Announces the Appointment of Barbara A. Heller as Chief Financial Officer -- more

Asterand: Local Small Business Honored as One of '50 Companies to Watch in Michigan' -- more

Elixir Pharmaceuticals Licenses Novel Growth Hormone Secretagogue Compound from Bristol-Myers Squibb for Treatment of Metabolic Disorders -- more

ABIOMED Announces Execution of a Definitive Agreement to Acquire Impella CardioSystems AG -- more

ExonHit Therapeutics Granted New Patent; Becomes Key Player in the Microarray Market -- more

Exelixis Files IND Application for Novel Anticancer Compound XL820 -- more

Xanthus Presents Symadex Gene Expression Study at AACR: Preclinical Study Hints at Potential for Multiple Sclerosis -- more

ACADIA Pharmaceuticals Announces $36 Million Financing -- more

Boston Scientific Corporation and Rubicon Medical Corporation Amend Agreements and Boston Scientific Exercises Option to Acquire Control of Rubicon -- more

Reviving an Old Drug: Critical Therapeutics relaunches an asthma drug with the help of Rhodia manufacturing -- more

Ensemble Discovery Names Richard F. Begley as CEO; Begley Leverages Knowledge of Chemistry, Biology and Engineering -- more

Cyberkinetics Receives Neuroport 510K Clearance; Acute Neural Monitor is Company's First Commercial Clinical Product -- more

Cyberkinetics Gives Update on BrainGate Clinical Trial -- more

Critical Therapeutics Submits Supplemental New Drug Application to FDA for ZYFLO -- more

Cyberkinetics Announces Results for Fiscal Year Ended December 31, 2004; Product Development and Clinical Progress Highlight Year -- more

Brain chip reads man's thoughts -- more

Sirna Therapeutics Appoints Dr. Keith Yamamoto to Chairperson of SAB -- more

Exelixis Initiates Phase I Trial for Anticancer Compound XL880 -- more

Critical Therapeutics Initiates Open-Label Study of ZYFLO; Study Provides Certain Patients Access to ZYFLO Prior to Commercial Availability -- more

Enanta Pharmaceuticals Achieves Milestone in Collaboration with Shionogi & Co., Ltd., as Phase 1 Studies Initiate in Japan on EP-013420, a First-In-Class Bridged Bicyclic Ketolide Antibiotic -- more

Alantos Pharmaceuticals Raises $20 Million in Private Placement -- more

Solexa Completes First Full Genome Sequence with Cluster-SBS Technology -- more

Lynx Stockholders Overwhelmingly Approve Solexa-Lynx Business Combination -- more

GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS -- more

Six-Month Results of Cyberkinetics' BrainGate Neural Interface System Pilot Study Presented at AAP Meeting -- more

Santhera Reaches Milestone in Serono Drug Discovery Collaboration -- more

Sirna Therapeutics Granted Two Key Patents on Its RNA Interference Technology -- more

Rolf Stahel Appointed as Chairman of Powdermed -- more

Critical Therapeutics Initiates Phase II Clinical Study of CTI-01 -- more

Sosei Co. Ltd: SOT-107 Granted Orphan Designation in Japan -- more

Astex achieves drug discovery milestone with Boehringer Ingelheim -- more

Rhodia Pharma Solutions and Critical Therapeutics Sign Long-Term Supply Agreement for Zileuton -- more

Dr Peter Ringrose joins Astex Board -- more

Astex granted patent covering use of crystal structure of human cytochrome P450 3A4, the most important drug metabolising enzyme in man -- more

Xantos Biomedicine AG Successfully Advances a Development Project for Roche -- more

Scion Pharmaceuticals Announces the Appointment of Dr. Barry A. Berkowitz as President and Chief Executive Officer -- more

Sirna Therapeutics and Targeted Genetics Form Huntington's Disease Collaboration -- more

ACADIA Pharmaceuticals Announces Partnership With Sepracor -- more

Trubion Announces Initiation of First Phase I Study in Rheumatoid Arthritis -- more

Exelixis Amends Collaboration With GlaxoSmithKline -- more

Sirna Therapeutics Launches Program to Treat Asthma With RNAi Technology -- more

Sirna Therapeutics Launches Program to Treat Diabetes with RNAi Technology -- more

Santhera Pharmaceuticals AG Completes First Round of Financing Raising Euro 14 Million -- more

Elixir Extends IP Surrounding SirT Deacetylases with Exclusive License to SirT2 and SirT3 Patents from University of California -- more

World Economic Forum Selects Memory Pharmaceuticals as 2005 Technology Pioneer -- more

Red Herring Selects Avalon Pharmaceuticals for Prestigious Red Herring Top 100 Innovators Award -- more

Sirna Therapeutics Launches Dermatology Division Targeting Permanent Hair Removal With siRNAs -- more

Spaulding Rehabilitation Hospital Joins Cyberkinetics' BrainGate Neural Interface System Pilot Study -- more

ZettaCore Named 2005 Technology Pioneer by World Economic Forum -- more

Astex chosen by the World Economic Forum as a Technology Pioneer for 2005 -- more

DrugMax, Inc. Secures $17 Million Private Placement -- more

Astex Awarded The Sunday Times Microsoft Tech Track 100 Research and Development Award 2004 -- more

Japanese drug maker Kyorin Pharmaceutical Co. Agrees to Buy Unlisted ActivX Biosciences Inc. for $21 million. -- more

Santhera Pharmaceuticals Announces the Appointment of Pierre Vankan, Ph.D. as Vice President, Drug Development and Global Project Management -- more

Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at Cleveland Clinic -- more

Positive Outcome of Phase I DNA Influenza Study: PowderMed announces first clinical trial results -- more

FDA Approves superDimension/Bronchus -- more

DrugMax and Familymeds Complete Merger -- more

Sosei Announces the Launch of its US Company Targeting the Development of CNS Compounds. Deal with Mitsubishi Pharma Corporation Provides the Platform -- more

Bristol-Myers Squibb Medical Imaging and IMCOR Pharmaceutical Co. Enter into Cross-Licensing Agreement for Ultrasound Contrast Patents -- more

ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Drug -- more

Astex Achieves Drug Discovery Collaboration Success with Schering AG -- more

Clinical MicroArrays Announces $7.5 Million Series A Financing -- more

Sirna Therapeutics Announces RNAi Therapeutic Development Program to Address Huntington's Disease -- more

Xanthus Initiates Second Phase 1 Trial for Symadex to Study Daily Dosing in Patients with Solid Tumors -- more

Cyberkinetics' Chief Scientific Officer, John Donoghue, Ph.D., Receives Discover Magazine's Innovations Award for Neuroscience; Cited for Work on Brain-Computer Interface -- more

Critical Therapeutics Appoints Pharmaceutical Industry Veteran Robert Zeiger as Independent Director -- more

Critical Therapeutics Reports Successful Multiple-Dose Phase I Study of CTI-01 -- more

PowderMed Initiates a Phase I Clinical Trial for a Novel Therapeutic Herpes Simplex Type 2 (HSV 2) DNA Vaccine -- more

Astex Strengthens Management Team - Martin Buckland Joins as Senior Vice President, Business Development -- more

Initial Results of Cyberkinetics' BrainGate Neural Interface System Pilot Study Presented at AAPM&R Meeting -- more

Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: TGRV) Completes Merger, Name Change and Reincorporates in Delaware -- more

Santhera Pharmaceuticals and Genzyme Enter Into Option and License Agreement for Discovery of Therapies for Muscle Diseases -- more

Critical Therapeutics to Begin Phase II Study of Zileuton for Moderate to Severe Acne; Efficacy and Safety Trial to be Conducted in up to 90 Patients -- more

ZettaCore Expands Management Team With Appointment of Chief Executive and Vice President -- more

Astex ranked top biotech company for the second year running in The Sunday Times Microsoft Tech Track 100 -- more

NuVios Names C. Richard Lyttle President & CEO -- more

Cambrios founder Angela Belcher wins MacArthur 'Genius' award -- more

Solexa & Lynx Merge to Create Future-Sequencing Powerhouse -- more

Solexa Announces Successful Closure of $14.4m financing -- more

Ludwig Institute for Cancer Research and PowderMed Initiate a Phase I Clinical Trial for a Novel Therapeutic Cancer Vaccine -- more

Illumina to Conduct Large-Scale Genotyping Study for North American Rheumatoid Arthritis Consortium -- more

ACADIA Clinical Study Shows ACP-103 Improves Clinical Profile of Antipsychotic Drug Treatment -- more

Elixir Pharmaceuticals Announces Issuance of Patent for "Methods of Identifying Lifespan Altering Agents" and Presentation of Data on Discovery of SIRT1 Inhibitors -- more

William K. Heiden Appointed CEO of Elixir Pharmaceuticals -- more

Graffinity Pharmaceuticals AG and MyoContract AG Merge to Form Santhera Pharmaceuticals AG -- more

Sirna Therapeutics' First IND Filing Applies Novel RNAi Therapy to the Treatment of Age-Related Macular Degeneration -- more

ACADIA Pharmaceuticals to Expand Scandinavian Chemistry Operations -- more

Enanta Pharmaceuticals Raises $20 Million in New Financing and Initiates Phase 1 Clinical Trial on EP-013420 -- more

Solexa Announces the Appointment of John West as New CEO -- more

Concentric Medical: FDA Clears First Device for Removing Blood Clots in Stroke Patients -- more

Sirna Therapeutics' Collaborator Publishes a Study on RNAi Technology Targeting Neurodegenerative Diseases -- more

Illumina To Perform Large-Scale Mouse Genotyping Study For The Wellcome Trust Centre -- more

Illumina Receives $1.2 Million Grant From The National Institutes Of Health -- more

Exelixis Appoints George Poste to Board of Directors -- more

Xanthus Receives Patent on Technology to Measure Gastric Emptying -- more

ACADIA Study Links ACP-104 (N-desmethylclozapine) to Improved Cognition in Schizophrenia Patients -- more

Cyberkinetics Named Among Top 15 Emerging Life Sciences Companies of 2004 -- more

Sirna Therapeutics & Archemix Form Exclusive Aptamer Manufacturing Alliance -- more

Enanta Pharmaceuticals and Shionogi & Co., Ltd. Sign Agreement for Development and Commercialization of the First-in-Class Bridged Bicyclic Ketolide Antibiotic EP-013420 in Japan and East Asian Countries -- more

Critical Therapeutics to Initiate Phase I Study of Anti-Inflammatory Compound, CTI-01 -- more

Genomas and Illumina Form Strategic Alliance on Physiogenomics of Metabolic Syndrome -- more

SciQuest Stockholders Approve Acquisition by Trinity Ventures -- more

Astex reveals structure of key drug metabolizing enzyme - cytochrome P450 3A4 - in Science -- more

Trubion Raises $32 Million in Series B Financing to Fund Advancement of Lead Product Candidates -- more

Cellomics and GE Healthcare Collaborate To Provide Faster and More Effective Cellular Screening Solutions -- more

Exelixis Files IND Application for Anticancer Compound XL999 -- more

ACADIA Pharmaceuticals Presents Favorable Results From Phase Ib/IIa Clinical Trial and PET Study of ACP-103 -- more

Nuvelo Announces the Completion of Its Phase 2 Alfimeprase Trial in Acute Peripheral Arterial Occlusion -- more

Cellomics, Inc. Announces Appointment of Business Development Executive -- more

Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer -- more

Cellomics and GE Healthcare Sign License Agreements to Expand Availability of High Content Screening -- more

Scientists vote Detroit's Asterand 'best place to work.' -- more

ExonHit develops a new improved formulation of Ikomio' for ALS patients -- more

Sosei Initiates Phase I Clinical Trial of Oral Sou-001 -- more

Lexicon Genetics Appoints Gregory M. Landes, Ph.D. Vice President of Biotherapeutics -- more

Sirna Therapeutics Evaluating RNAi to Treat Huntington's Disease -- more

Astex extends research collaboration with Aventis -- more

Inverness Medical Innovations, Inc. Acquires Advantage Diagnostics Corporation -- more

Sirna Therapeutics Demonstrates Systemic Efficacy of siRNAs in Multiple Animal Models -- more

Corixa and GlaxoSmithKline announce results of two studies of BEXXAR following chemotherapy as first-line treatment of non-Hodgkin's lymphoma presented at ASCO -- more

Nuvelo Announces Preliminary Phase 2 Alfimeprase Results in Acute Peripheral Arterial Occlusion Trial Presented Today at the Vascular 2004 Annual Meeting -- more

Exelixis Initiates Phase 1 Trial for Anticancer Compound XL647 -- more

Critical Therapeutics, Inc. Announces Pricing of Initial Public Offering -- more

ACADIA Pharmaceuticals Announces Initial Public Offering -- more

Xanthus Commences Phase I/II Clinical Trial for Xanafide Amonafide in Patients -- more

PowderMed Spins Out Of Chiron With $34.5 Million Series A -- more

PowderMed launched in spin out of powder injection DNA vaccine programmes from Chiron vaccines -- more

Targacept files for initial public offering -- more

Roche adopts Cellomics Store and EMC Centera for High Content Screening Solution -- more

Astex achieves second milestone in Alzheimer's drug discovery collaboration with AstraZeneca -- more

Dynogen Secures $50 million Series B Financing to Advance its Pipeline of Genitourinary and Gastrointestinal Development Programs -- more

Brain implant devices approved for trials -- more

Memory Pharmaceuticals Stock Up After Delayed IPO -- more

ActivX Biosciences Announces Agreement with Gilead Sciences for Protein Activity Profiling -- more

Memory Pharmaceuticals Corp. Announces Pricing of Initial Public Offering -- more

Exelixis Describes the Discovery of Novel Cancer Targets at AACR -- more

Check Point Software Completes Zone Labs Acquisition -- more

Texas Children's Hospital Implants First MicroMed/DeBakey Child Venticular Assist Device -- more

Lynx and Solexa Jointly Acquire DNA Technology Assets -- more

Astex, The Wellcome Trust, The Institute of Cancer Research and Cancer Research Technology announce major cancer drug discovery collaboration -- more

Exelixis Granted Orphan Drug Designation for Anticancer Agent XL119 -- more

Cyberkinetics: Brain Power -- more

Astex announces drug discovery alliance with Boehringer Ingelheim -- more

The First Minituarized Heart Pump for Children Approved -- more

Acadia Pharmaceuticals Inc. Files Registration Statement For Initial Public Offering -- more

Exelixis Publishes World's Most Comprehensive Collection of Functional Gene Knockouts in a Multicellular Organism -- more

Graffinity Pharmaceuticals Completes Euro 15 Million Series C Round of Financing -- more

Exelixis Files IND Application for Anticancer Agent XL647 -- more

Vaughn M. Kailian Joins Elixir Pharmaceuticals As Chairman of the Board -- more

Concentric Medical: Tiny corkscrew stops strokes in tests -- more

Avalon Pharmaceuticals Discovers Prostate Cancer
Biomarker -- more

Targacept Announces Addition of Errol De Souza, Ph.D. to its Board of Directors -- more

HydroCision Sells Advanced Business to
Smith & Nephew -- more

Hypnion Names Dr. Robert Michael Poole Chief
Medical Officer -- more

ZettaCore Closes $17.5 Million in Series B
Financing -- more

Avalon Pharmaceuticals Announces Appointment of
James H. Meade, Ph.D. to Vice President for Business Development and the Promotion of Paul E. Young, Ph.D. to
Vice President of Research -- more

Enanta Pharmaceuticals Secures $12 Million Financing Under New Management -- more

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference -- more

Exelixis Appoints Chief Financial Officer -- more

Cellomics, Inc. announces completion of new financing and balance sheet restructuring -- more

ACADIA Pharmaceuticals Achieves Milestone as Allergan Advances Glaucoma Drug Candidate -- more

Dr. George M. Milne, Jr. Joins Rib-X Pharmaceuticals Board of Directors -- more

Accelerated Technologies Raises $32 Million To Advance Multiple Cardiovascular Device Opportunities -- more

Dynogen Pharmaceuticals, Inc. Enters Into Overactive Bladder Collaboration with Johnson & Johnson Pharmaceutical Research & Development -- more

Nancy S. Lurker Named Chief Exectuive Officer and President of ImpactRx -- more

ImpactRx Expands to Provide Decision Support on Dermatology Market -- more

Genpath Pharmaceuticals and Merck Enter into Potential $100 Million Deal for the Discovery of Novel Cancer Drugs -- more

Xanthus Life Sciences Secures $30.8 Million to Develop Its Personalized Anticancer Medicines and Names Dr. Richard T. Dean as Chief Executive Officer -- more

CTI Raises $56M in Series B; Asthma Product to
Benefit -- more

GenPath Pharmaceuticals Raises $42.7 Million
in Series B Funding -- more